Press Releases Crescita Therapeutics Inc.

Equities

Delayed Toronto S.E. Other stock markets 03:22:21 2024-05-27 pm EDT			5-day change	1st Jan Change
0.42 ^CAD	-2.33%		-10.64%	-14.29%

May. 08	Crescita Therapeutics Q1 Loss Widens, Revenue Rises	MT
May. 08	Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million	MT

Crescita Reports First Quarter 2024 Results	May. 08	BU
Crescita Reports Q4 and Fiscal 2023 Results	Mar. 13	BU
Crescita Reports Third Quarter 2023 Results	Nov. 08	BU
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid	23-08-29	BU
Crescita Reports Second Quarter 2023 Results	23-08-09	BU
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders	23-06-21	BU
Crescita Reports First Quarter 2023 Results	23-05-11	BU
Crescita Reports Q4 and Fiscal 2022 Results	23-03-15	BU
Crescita Reports Third Quarter 2022 Results	22-11-09	BU
Crescita Reports Second Quarter 2022 Results	22-08-10	BU
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders	22-05-12	BU
Crescita Reports First Quarter 2022 Results	22-05-11	BU
Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference	22-04-21	BU
Crescita Reports Q4 and Fiscal 2021 Results	22-03-23	BU
Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid	21-12-15	BU
Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis	21-12-14	AQ
Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®	21-12-13	BU
Crescita Reports Third Quarter 2021 Results and Appoints New Board Member	21-11-11	BU
Crescita Therapeutics : Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC	21-09-09	BU
Crescita Therapeutics : Acquires Minority Interest in The Best You®	21-09-07	BU

No results for this search